PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29077864-0	2018	Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.	Sofosbuvir	17-27	KRAS proto-oncogene, GTPase	Homo sapiens	154-157	
29077864-11	2018	Conclusions: Our findings support the concept of retreating with sofosbuvir + grazoprevir/elbasvir + ribavirin, for 16 weeks, genotype 1 or 4 DAA-experienced patients with proven NS5A or NS3 RASs.	Sofosbuvir	65-75	KRAS proto-oncogene, GTPase	Homo sapiens	187-190	
28877086-7	2017	Baseline NS3-RASs before retreatment were observed in two patients who failed a sofosbuvir/simeprevir regimen: D168V RAS was detected in a genotype-4 patient, whereas the complex RAS-pattern Q80K, I170V, R155K, D168E was observed in a genotype-1a patient.	Sofosbuvir	80-90	KRAS proto-oncogene, GTPase	Homo sapiens	9-12	
28877086-9	2017	CONCLUSION: These real-life findings indicated a high efficacy of sofosbuvir+NS5A-inihbitors in retreating NS3-experienced patients and also NS5A-experienced patients by using a 24-week course ribavirin-containing regimen.	Sofosbuvir	66-76	KRAS proto-oncogene, GTPase	Homo sapiens	107-110	
25002352-4	2014	The NS3/4A inhibitor simeprevir and NS5B inhibitor sofosbuvir have recently been licensed and can reduce the length of antiviral treatment, improve response rates, and allow for interferon-free regimens for some HCV genotypes.	Sofosbuvir	51-61	KRAS proto-oncogene, GTPase	Homo sapiens	4-7	
26209383-3	2015	We demonstrate that sofosbuvir-based therapy resulted in cure of hepatitis C in a patient who had relapsed during combination therapy with an NS5A inhibitor, an NS3 protease inhibitor and ribavirin, as well as treatment failures to multiple courses of interferon-based therapy.	Sofosbuvir	20-30	KRAS proto-oncogene, GTPase	Homo sapiens	161-164